Our mission is to use the heterogeneity of myeloid cells as an in vivo sensor to track inflammatory responses and as a target for therapeutic intervention.
The Myeloid Cell Immunology team led by Jo Van Ginderachter studies the ontogeny, function, and therapeutic targeting of different myeloid and immunoregulatory cell populations in cancer and during infectious diseases, with a particular focus on, and expertise in, macrophage biology. To do so, we employ cutting-edge models and translate to human samples, applying state-of-the-art molecular and genetic technologies such as single cell RNA-sequencing, CITE-sequencing, lipidomics, epigenomics and spatial transcriptomics, the generation of novel transgenic mouse strains and the strategic exploitation of our in house nanobody production facility (nanobodies as vehicles for in vivo molecular imaging and therapeutic targeting). Consequently, this research pipeline encompasses both fundamental and applied research projects, with an ultimate goal to valorize our research.